Chronic and Acute Leukemias in Adults

• 1. Retroviruses and Onc Genes in Human Leukemias and Lymphomas.- 1.1 Introduction.- 1.2 Onc Genes in Leukemogenesis.- 1.3 Retroviruses in Human Leukemia-Lymphoma.- 2. Study of Differentiation and Proliferation of Leukemic Cells Using Myeloid Leukemia Cell Lines.- 2.1 Introduction: Establishment of Human Myeloid Leukemia Cell Lines.- 2.2 Human Erythroleukemia Cell Lines.- 2.3 Study of Granulocyte Differentiation Using Myeloid Leukemic Cell Lines.- 2.4 Induction of Macrophage-Like Differentiation of Human Acute Myelogenous Cells.- 2.5 Genetic Analysis of Myeloid Differentiation.- 2.6 Hormonal Modulation of Leukemic Cell Growth.- 2.7 An In Vitro Model for Chemotherapy of Acute Myelogenous Leukemia.- 2.8 Conclusion.- Acknowledgements.- References.- 3. Biological Markers in Lymphoproliferative Disorders.- 3.1 Introduction.- 3.2 Immunological Markers.- 3.3 Chronic B-Cell Malignancies.- 3.4 Chronic T-Cell Malignancies.- 3.5 Cytochemistry of Acid Hydrolases.- 3.6 Chromosomes.- 3.7 Conclusions.- Acknowledgements.- References.- 4. Surface Marker Analysis of Acute Myeloblasts Leukemia.- 4.1 Introduction.- 4.2 Differentiation of Normal Myeloid Cells.- 4.3 Detection of Myeloid-Lineage Antigens by Heteroantisera.- 4.4 Production of Monoclonal Antibodies to Myeloid Cell Surface Antigens.- 4.5 Monoclonal Antibodies Reactive with Human AML Cells.- 4.6 Expression of Myeloid Differentiation Antigens on AML Cells.- 4.7 Future Directions.- References.- 5. Classification of 358 Cases of Acute Myeloid Leukemia by FAB Criteria: Analysis of Clinical and Morphologic Features.- 5.1 Introduction.- 5.2 Clinical and Morphologic Characteristics of the FAB Classes.- 5.3 Comparison of FAB Classes of AML.- 5.4 Discussion.- References.- 6. Chemosensitivity of In Vitro Colony Forming Units as a Predictorof Response to Antileukemic Drugs.- 6.1 Introduction.- 6.2 Colony Assays.- 6.3 Quantitation of Sensitivity to Antileukemic Drugs.- 6.4 Correlations Between In Vitro Chemosensitivities of L-CFU and Clinical Response of the Patient.- 6.5 Summary.- References.- 7. Post-Remission Therapy for Acute Myelogenous Leukemia.- 7.1 Introduction.- 7.2 Role of Induction Therapy on Remission Duration.- 7.3 Role of Consolidation Therapy on Remission Duration.- 7.4 Role of Maintenance Chemotherapy in Prolonging Remissions.- 7.5 The Role of Immunotherapy in Maintenance.- 7.6 Prognostic Variables Predicting for Prolonged Remission Duration.- 7.7 Central Nervous System Leukemia.- 7.8 Bone Marrow Transplantation.- 7.9 Summary and Conclusions.- Acknowledgement.- References.- 8. The Role of Marrow Transplantation in the Treatment of Leukemia.- 8.1 Introduction.- 8.2 Donor Selection.- 8.3 Preparative Regimens.- 8.4 Techniques of Marrow Transplantation.- 8.5 Clinical Results in Acute Nonlymphoblastic Leukemia (ANL).- 8.6 Clinical Results in Acute Lymphoblastic Leukemia (ALL).- 8.7 Clinical Results in Chronic Granulocytic Leukemia (CGL).- 8.8 Leukemic Recurrence After Transplantation.- 8.9 Graft-Versus-Host Disease (GVHD).- 8.10 Infectious Complications, Including Interstitial Pneumonia.- 8.11 Other Organ Toxicities.- 8.12 Summary.- Acknowledgements.- References.- 9 Hyperleukemias in Adult Leukemia.- 9.1 Introduction.- 9.2 Acute Myelocytic Leukemia.- 9.3 Chronic Myelocytic Leukemia.- 9.4 Acute Lymphocytic Leukemia.- 10 New Developments in the Etiology, Diagnosis, Treatment and Prevention of Infectious Complications in Patients with Leukemia.- 10.1 Introduction.- 10.2 Changing Patterns of Infections.- 10.3 New Developments in Evaluation and Diagnosis.- 10.4 Developments in Antimicrobial Therapy.-10.5 New or Evolving Syndromes in Management of Infections in the Adult Leukemic.- 10.6 Recent Developments in Adjuvant Therapy.- 10.7 Current Concepts in Infection Prevention in Acute Leukemia.

'...these essays serve as well-referenced reviews of subjects on which the reader is not an expert, so condensing many a literature search... a good investment for academic institutions.' N.T.J. O'Connor, John Radcliffe Hospital, Oxford 'This book will be of particular interest to oncologists and hematologists who specialize in the treatment of leukemia. ...the best resource available on the study and treatment of leukemias.' The New England Journal of Medicine (March 1986)